A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-2

A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-2

Introduction: Mezigdomide (MEZI), a novel oral cereblon E3 ligase modulator (CELMoD™), induces maximal degradation of Ikaros/Aiolos leading to increased MM cell apoptosis and immune-stimulatory effects. MeziKd has shown potent synergistic antiproliferative activity in MM cell lines resistant to lena...

Full description

Bibliographic Details
Main Authors: PGR Md, MA Phd, JRB Md, CCM Phd, MAD Md, CTH Md, JKM Phd, AOM Phd, RZOM Phd, Md HQ, MSR Md, ARM Phd, DW Md, ZZ Phd, VHM Phd
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S253113792300977X

Internet

http://www.sciencedirect.com/science/article/pii/S253113792300977X

Similar Items